- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00388453
Efficacy of Dx-pH Probe in Diagnosing Extra-esophageal Reflux Disease (ADHERE)
May 24, 2017 updated by: Michael Vaezi, Vanderbilt University Medical Center
ADHERE Study: Application of Dx-pH Catheter for Extra-esophageal Reflux Evaluation
The purpose of this study is to establish the clinical application of a new device that records pH changes in the hypopharynx.
The investigators also aim to compare the consistency of distal esophageal pH with hypopharyngeal pH using both the "short" and the "long" catheters in patients.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Gastroesophageal reflux disease (GERD) has been linked to many disorders and can be diagnosed through a variety of modalities utilizing 24 hour ambulatory pH monitoring which can register the duration, pattern and symptom correlation of distal esophageal acid exposure.
This can be accomplished via a catheter probe connected from outside the body and placed through a nostril, advanced past the hypopharynx and down into the distal esophagus.
Or, a small pH detector temporarily implanted in the distal esophagus during endoscopy can record reflux events.
However, despite available technologies, there has long been a deficiency in detecting extra-esophageal reflux in the upper esophagus/ hypopharynx.
This is of interest for gastroenterologists, otolaryngologists, and pulmonologists in the evaluation of extra-esophageal reflux as a potential culprit for asthma, chronic cough, laryngitis, globus, and non-cardiac chest pain.
Until now, there has not been a device sensitive enough for accurately detecting extra-esophageal reflux (EERD) and clinicians have relied upon subjective response to empiric treatment with acid reducing medications to determine whether acid reflux was at the root of the symptoms.
There are currently no well designed published studies with this device to assess its role in this group of difficult to treat patients.
Study Type
Interventional
Enrollment (Actual)
47
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Tennessee
-
Nashville, Tennessee, United States, 37232
- Vanderbilt Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Male and female volunteers aged 18 to 65 years old.
- Control group: No known history of GERD or EERD or prior PPI use.
- GERD group: Patients with known history of GERD based on prior response to either histamine inhibitors (H2 blockers) or proton pump inhibitors (PPIs) and/or endoscopic esophagitis identified at endoscopy.
- EERD group: Patients with chronic cough, asthma and laryngeal findings felt to be GERD related.
Exclusion Criteria:
- Use of H2 blockers or PPIs within one week prior to and during the study for the GERD and EERD patients. No prior PPI use is allowed for the control population.
- Use of antacids (Rolaids, Tums, Pepto-Bismol, etc.) within one day prior to or during the study.
- Esophageal motility abnormalities (achalasia, esophageal spasm, severe dysphagia)
- Expected non-compliance.
- Positive history of ongoing alcohol or tobacco use and inability to refrain from using either during study duration (24 hours).
- Recent nasal surgery or nasal obstruction.
- Significant medical conditions that, in the investigator's judgment, would compromise the subject's health and safety (mental disability, psychiatric impairment, inability to read or comprehend the consent form)
- Pregnancy
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: 1
Healthy volunteers with no history of GERD or EERD or Proton Pump Inhibitor (PPI) use
|
24 hour ph monitoring
procedure to measure pH at the Lower esophageal sphincter (LES) and Upper esophageal sphincter (UES)
|
|
Experimental: 2
subject is known to have GERD based on symptoms and previous positive response to PPI
|
24 hour ph monitoring
procedure to measure pH at the Lower esophageal sphincter (LES) and Upper esophageal sphincter (UES)
|
|
Experimental: 3
subject is known to have EERD based on symptoms and previous positive response to PPI
|
24 hour ph monitoring
procedure to measure pH at the Lower esophageal sphincter (LES) and Upper esophageal sphincter (UES)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Decrease in pH From Baseline to <4
Time Frame: 24 hours
|
The three study groups underwent dual pH measurements of the oropharyngeal as well as esophageal acid exposure employing the regular length probe for the oropharynx and the custom-designed long probe for the distal esophagus.
The reason for the custom-designed esophageal measurement was to ensure that events noted in the oropharynx originated distally and were of gastric source.
Measurements for the two locations were time synchronized to ensure accuracy.
Calculations were based on length of time spent in upright and supine positions, and a combination of the two positions.
|
24 hours
|
|
Decrease in pH From Baseline to <5
Time Frame: 24 hours
|
The three study groups underwent dual pH measurements of the oropharyngeal as well as esophageal acid exposure employing the regular length probe for the oropharynx and the custom-designed long probe for the distal esophagus.
The reason for the custom-designed esophageal measurement was to ensure that events noted in the oropharynx originated distally and were of gastric source.
Measurements for the two locations were time synchronized to ensure accuracy.
Calculations were based on length of time spent in upright and supine positions, and a combination of the two positions.
Reflux event was calculated for a drop in pH from baseline to either <4, or <5, or <6 and each event had to last more than 5 seconds and could not be during the meals.
|
24 hours
|
|
Decrease in pH From Baseline to <6
Time Frame: 24 hours
|
The three study groups underwent dual pH measurements of the oropharyngeal as well as esophageal acid exposure employing the regular length probe for the oropharynx and the custom-designed long probe for the distal esophagus.
The reason for the custom-designed esophageal measurement was to ensure that events noted in the oropharynx originated distally and were of gastric source.
Measurements for the two locations were time synchronized to ensure accuracy.
Calculations were based on length of time spent in upright and supine positions, and a combination of the two positions.
Reflux event was calculated for a drop in pH from baseline to either <4, or <5, or <6 and each event had to last more than 5 seconds and could not be during the meals.
|
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Number of Reflux Events
Time Frame: 24 hours
|
Reflux event was calculated for a drop in pH from baseline to <6 and each event had to last more than 5 seconds and could not be during the meals.
|
24 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Michael F Vaezi, MD, PhD, MS, Vanderbilt University
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2006
Primary Completion (Actual)
September 1, 2012
Study Completion (Actual)
July 1, 2013
Study Registration Dates
First Submitted
October 13, 2006
First Submitted That Met QC Criteria
October 13, 2006
First Posted (Estimate)
October 16, 2006
Study Record Updates
Last Update Posted (Actual)
June 27, 2017
Last Update Submitted That Met QC Criteria
May 24, 2017
Last Verified
May 1, 2017
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 060860
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.